Antimicrobial therapy for bacterial infections

Abstract

The disclosure provides compounds and methods to treat bacterial pathogenesis, and demonstrates that the S. aureus pigment is a virulence factor and potential novel target for antimicrobial therapy.

Description

[0001] Cross References to Related Applications [0002] This application claims priority under 35 U.S.C. §119 to U.S. Provisional Patent Application Serial No. 60 / 800,564, filed May 12, 2006, which is hereby incorporated by reference. Related application PCT / US06 / 14486 is hereby incorporated by reference. [0003] Statement Regarding Federally Funded Research [0004] This application was funded in part by grant numbers AI048694, GM50694, GM65307, and GM073216 awarded by the National Institutes of Health. The Government may have certain rights in this invention. Background technique [0005] Ogston (1881) used the genus Staphylococcus to describe grape-like bacteria (staphylo = grape, Greek) collected from the pus of surgical abscesses. Shortly thereafter, Rosenbach (1884) isolated the pathogen in pure culture and proposed that it The species name of Staphylococcus aureus (S.aureus) (golden, Latin). [0006] After entering the 1970s, the era of antimicrobial therapy has ...

AI Technical Summary

Problems solved by technology

Third, traditional therapies impose a "live-or-die" challenge on bacteria, whereby there is strong selective pressure to develop resistance to antimicrobial agents

Finally, many existing antibiotics have a very broad spectrum of activity, with the side effect of clearing the composition of many normal bacterial flora, leading to undesired complications such as Clostridium difficile colitis or secondary fungal infections (such as Candida spp. )

Images